Rimón R, Lepola U, Jolkkonen J, Halonen T, Riekkinen P
Department of Psychiatry, University of Helsinki, Finland.
Biol Psychiatry. 1995 Dec 1;38(11):737-41. doi: 10.1016/0006-3223(95)00076-3.
Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 11 patients with panic disorder (PD) prior to and following 7 months of treatment with alprazolam or imipramine and in six neurological control patients. Although a clear treatment response was observed in patients with PD, neither alprazolam nor imipramine significantly changed CSF GABA during the treatment period. A negative correlation was demonstrated between baseline CSF GABA and posttreatment overt psychopathology. Low pretreatment level of CSF GABA correlated significantly with poor therapeutic outcome, judged by the amount of anxiety and depression as well as by the frequency of panic attacks at the end of follow-up.
对11名惊恐障碍（PD）患者在接受阿普唑仑或丙咪嗪治疗7个月前后以及6名神经科对照患者的脑脊液（CSF）γ-氨基丁酸（GABA）水平进行了测量。尽管在PD患者中观察到了明显的治疗反应，但在治疗期间，阿普唑仑和丙咪嗪均未显著改变脑脊液GABA水平。基线脑脊液GABA与治疗后明显的精神病理学之间呈负相关。脑脊液GABA的低预处理水平与不良治疗结果显著相关，这是根据随访结束时的焦虑和抑郁程度以及惊恐发作频率来判断的。
